Aflibercept in diabetic macular oedema: Added benefit not proven

There were no relevant differences between the treatment groups for patients in whom the area of greatest visual acuity is also affected. For other patients, data were lacking.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1A0Z153